Evaxion Biotech A/S Operating Income

As of the most recent data (March 2026), EVAX shows a operating income of $-9.2M. That compares with $-14M in the prior-year period — up 35.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EVAX's operating income is now $-9.2M (was $-14M) — a 35.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Evaxion Biotech A/S is outperforming or lagging.

Tracking EVAX's operating income over time shows whether Evaxion Biotech A/S is scaling, shrinking, or reshaping that part of the business. The current reading is $-9.2M That compares with $-14M in the prior-year period — up 35.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Evaxion Biotech A/S's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-9.2M) with ownership activity and broader fundamentals.

Evaxion Biotech A/S's operating income is $-9.2M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.